• The decision to inject gadolinium-based contrast agents (GBCAs) or not should be made, if
possible, together with the patient. Wellinformed patients are able to choose the most …

LETTERS TO THE EDITOR 324 radiology. rsna. org n Radiology: Volume 279: Number 1—
April 2016 meglumine or gadopentatate dimeglumine. A statistically significant and …

Radiology: Volume 288: Number 2—August 2018 n radiology. rsna. org 435 potential and its
potential to cause allergic-like reactions (10). All these factors must be included in a …

Malayeri et al [1] write,“At present, there is no evidence suggesting that gadolinium
deposition in the brain alters neurologic function.” Where is the evidence for this statement …

I read with great interest the comprehensive review article entitled “Safe Use of Contrast
Media: What the Radiologist Needs to Know” by Dr Beckett and colleagues (1) in the …

Gadolinium-based contrast agents (GBCAs) consist of gadolinium ions and a chelating
agent that binds the gadolinium ion tightly so that its toxicity is not manifested. However, in …

When Tomonori Kanda published at the end of 20131 that gadolinium-based contrast
agents (GBCAs) might be the cause of hyperintensities in the dentate nucleus, the …

Strong opinions—and emotions—abound. Many physicians believe that macrocyclics are
“safer” than linear agents—after all, less material seems to be retained with most …

Editor: We thank Dr Patel and colleagues (1) for a timely metaanalysis of adverse events
associated with intrathecal administration of gadolinium-based contrast agents (GB-CAs) …

Gadolinium (Gd) retention in the body, especially in the brain, is a topic of ongoing debate
since Kanda et al1 in 2013 first reported that hyperintensity in the brain on unenhanced …